A new way to keep dialysis access working well
Official title: Contact Pathway Inhibitor to Prevent Vascular Access Failure
Funded at Aronora, INC. · NIH-11121787 · Data updated 2026-11-12
This project is developing a new medication to help keep the special tubes used for kidney dialysis, called AV grafts, open and working for patients with end-stage kidney disease.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aronora, INC. NIH-funded |
| Lab location | 1 site (Portland, UNITED STATES) |
| Project start | June 1, 2023 |
| Project end | June 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $1,331,056 |
| NIH project number | 5R44HL167467-03 |
| Project ID | NIH-11121787 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are patients with end-stage kidney disease who use AV grafts for hemodialysis and experience issues with their grafts becoming blocked.
✕Less likely to help
Patients who do not use AV grafts for hemodialysis or who do not have end-stage kidney disease would not directly benefit from this specific treatment.
What this research studies
For people with end-stage kidney disease who need hemodialysis, keeping their vascular access working is crucial. While AV fistulas are often preferred, many patients, especially Black/African American individuals and women, rely on AV grafts which can frequently become blocked or infected. This research focuses on creating a unique medicine, AB023, designed to prevent these grafts from clotting. By keeping the grafts open longer, patients can continue their life-saving dialysis treatments more smoothly. We've already completed an early clinical trial that suggests this new medicine is safe for patients.
Why it matters
Potential benefit: If successful, this new medication could significantly extend the life of AV grafts, reducing complications and improving the quality of life for dialysis patients.
How similar studies have gone: A pilot phase 2a clinical trial has already been completed, showing early indications that this approach may be safe in medically complex patients.
Where this research is happening
-
Aronora, INC.
Portland, United States Active
Researchers
- Principal investigator: Lorentz, Christina U — Aronora, INC.
- Study coordinator: Lorentz, Christina U
Related research
Other NIH-funded projects on the same topics.
-
Contact Pathway Inhibitor to Prevent Catheter-Related Thrombosis
A new treatment approach uses AB023 (gruticibart) aimed at preventing blood clots and inflammation around central venous catheters to keep them working safely in cancer patients.
-
A New Way to Prevent Blood Clots in Catheters
This project is developing a new medicine to help prevent blood clots and inflammation in central venous catheters, especially for patients who need these catheters for medical treatments.
-
A new treatment to prevent complications in dialysis access for kidney patients
This study is testing a new medication called AB023 to see if it can help improve the success and lifespan of the grafts used for dialysis in patients with kidney disease, especially focusing on helping Black patients who often face more challenges with these procedures.
-
Targeting thrombopoietin to treat blood cancers
This study is testing a new drug called AB062 to help people with myeloproliferative neoplasms (MPNs) by lowering the levels of a protein that causes too many blood cells to be made, which could lead to better health and a better quality of life for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.